Myelofibrosis: best practices, controversies and 2019 update.

Myelofibrosis: best practices, controversies and 2019 update. Expert Rev Hematol. 2019 Nov 08;: Authors: Cruz NM, Gergis U, Silver RT Abstract Introduction: Recent advances in the prognostic scheme and treatment of primary and secondary myelofibrosis (MF) have resulted in an overwhelming amount of clinical information to assimilate. The authors believe a comprehensive review that summarizes the most recent published literature, could serve as guidelines for the practicing hematologist.Areas Covered: The authors provide a summary of landmark articles regarding epidemiology, symptoms and pathogenesis of disease. The authors conducted a systematic literature review to answer questions regarding: differences between primary myelofibrosis (PMF) and secondary myelofibrosis (SMF), appropriate use and selection of the current risk-stratification models, early versus late treatment of MF and current practices in allogeneic hematopoietic stem cell transplantation (allo-HCT) for MF. The authors conclude the article with their clinical opinion based on their experience and literature review. The purpose of this article is to identify current practices, address any variation, identify and investigate conflicting results and produce statements to guide decision-making.Expert Opinion: In this section the authors advocate for and provide examples of a standardized way of incorporating future discoveries in the pathogenesis and risk-stratification models of MF. They also ...
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research

Related Links:

Publication date: Available online 9 December 2019Source: Canadian Journal of CardiologyAuthor(s): Eli Muchtar, Grace Lin, Martha GroganAbstractLight chain (AL) amyloidosis is a systemic syndrome characterized by progressive organ dysfunction leading to organ failure and death. The heart is the most commonly involved organ and the leading determinant of short and long-term survival. Pathogenic free light chains, fragments of intact immunoglobulins, are the amyloidogenic protein and are secreted by clonal bone marrow plasma cells. The goal of therapy is to cut-off the supply of these pathogenic light chains to allow organ r...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
Authors: Zhang X, Tenerelli K, Wu S, Xia X, Yokota S, Sun C, Galvao J, Venugopalan P, Li C, Madaan A, Goldberg JL, Chang KC Abstract BACKGROUND: Glaucoma, the number one cause of irreversible blindness, is characterized by the loss of retinal ganglion cells (RGCs), which do not regenerate in humans or mammals after cell death. Cell transplantation provides an opportunity to restore vision in glaucoma, or other optic neuropathies. Since transplanting primary RGCs from deceased donor tissues may not be feasible, stem cell-derived RGCs could provide a plausible alternative source of donor cells for transplant. OBJ...
Source: Restorative Neurology and Neuroscience - Category: Neurology Tags: Restor Neurol Neurosci Source Type: research
(NIH/National Cancer Institute) New findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic leukemia (B-ALL) that has relapsed. Those treated with blinatumomab had longer survival, experienced fewer severe side effects, had a higher rate of undetectable residual disease, and were more likely to proceed to a stem cell transplant.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Multidisciplinary, cancer-specific geriatric assessment to create an individualized optimization plan appears to improve outcomes in older patients undergoing hematopoietic cell transplantation (HCT), researchers report.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Transplantation News Source Type: news
Bone Marrow Transplantation, Published online: 10 December 2019; doi:10.1038/s41409-019-0772-1Oral verruciform xanthoma associated with stem cell transplantation and graft versus host disease in a paediatric patient
Source: Bone Marrow Transplantation - Category: Hematology Authors: Source Type: research
Bone Marrow Transplantation, Published online: 10 December 2019; doi:10.1038/s41409-019-0770-3Immunogenicity of the inactivated influenza vaccine in children who have undergone autologous stem cell transplant
Source: Bone Marrow Transplantation - Category: Hematology Authors: Source Type: research
Source: Annals of Hematology - Category: Hematology Source Type: research
As this article notes, researchers have recently suggested that the benefits to heart function observed over many years of stem cell therapies are not in fact due to any action of the cells themselves, not even cell signaling mechanisms such as release of exosomes, but are rather due to an immune response to the transplanted cells. The study reported here illustrates the point by showing some degree of regeneration of injured heart tissue to take place in mice when the debris of dead cells is transplanted. We might compare these findings with the body of work showing that delivery of exosomes can spur cardiac regeneration;...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
(Dana-Farber Cancer Institute) A new analysis shows that a donor stem cell transplant following treatment with an immune checkpoint inhibitor is generally safe and produces good outcomes for patients with Hodgkin lymphoma.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Autologous hematopoietic stem cell transplants have increased globally, but predominantly in high income nations, and there are marked disparities in usage.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Epidemiology | Hematology | Stem Cell Therapy | Stem Cells | Transplants